Canada's Drug and Health Technology Agency

Understanding Drug Processes in Canada

From Development to Post-Market Surveillance, and Factors Impacting Decision-Making

Sudha Kutty

Executive Vice-President,

Evidence, Products, and Services

April 29, 2024

Disclosure

- We are funded by contributions from the Canadian federal, provincial, and territorial ministries of health, except for Quebec.
- We receive application fees from the pharmaceutical industry for:
    - Reimbursement Review processes, including those used for
        - oncology drugs
        - non-oncology drugs
        - plasma protein and related products reviewed through the interim process
    - Scientific Advice

Overview

About Us

Our Role in the Drug Approval Process

Our Work Related to Pain

- Drug Submissions for Pain

Collaborations to Improve the System

How to Get Involved

We Are a Trusted pan-Canadian Source of Credible Health Care Evidence



We are integral to the effective management of drugs and health technologies in Canada

We are experts in scientific research

We understand the importance of timely, relevant evidence to inform decision-making



We provide guidance in a rapidly changing environment

How Drug Reimbursement Decisions Are Made in Canada

Health Canada:
Is it safe? Does it work?

Patented Medicine Prices Review Board:
Is the price excessive compared with some other developed countries?

CADTH:
How does it compare with existing treatment options? Is it good value?

Federal, provincial, and territorial public drug plans and the pan-Canadian Pharmaceutical Alliance:
Is it needed? Is it affordable?

Drug Reimbursement Review Life Cycle





Our Work Related to Pain

- **Drug Reimbursement Reviews**
- **Post Market Drug Evaluations (PMDEs)**
  - Currently 8 pain-related projects: 6 are opioid-related and 2 are CGRP inhibitors for migraines
- **Health Technology Reviews**
  - Example: Internet-Delivered Cognitive Behavioural Therapy in the Treatment of Chronic Non-Cancer Pain

Drug Reimbursement Reviews for Pain

Over the Past 5 Years

Therapeutic area	Brand (generic)	Recommendation	Year
Migraine	Botox resubmission (onabotulinumtoxinA)	Reimburse	2019
	Aimovig (erenumab)	Reimburse	2020
	Ajovy (fremanezumab)	Reimburse	2021
	Emgality (galcanezumab)	Reimburse	2021
	Vyepti (eptinezumab)	Reimburse	2022
	Nurtec ODT (rimegepant)	Withdrawn	2023
	*Qulipta (atogepant)	Reimburse	2023
	†Qulipta (atogepant)	Active	2024

* Review was for episodic migraine
† Review is for chronic migraine

Collaborations to Improve the System

Examples of how we're working with patients, clinicians, and industry

Formulary Management Expert Committee (FMEC):

Patients, Clinicians

A sandbox to test different ways of working (i.e., inviting patients to present and observe presentations)

Time-Limited Recommendations:

Industry

Aims to help provide earlier access to promising new treatments for people in Canada living with severe, rare, or debilitating conditions

Target Zero:

Industry

Leveraging our common goal to improve access to drugs for patients through aligned reviews

Target Zero

Reimbursement Review Timing: Post–Notice of Compliance (NOC)



Parallel Review Timing: Pre-NOC



Patients and Community Engagement

Patients, families, communities, and patient groups are involved in our work by:

- Providing input for Reimbursement Reviews
- Collaborating in specific assessments as part of advisory groups or expert committees
  - Canadian Drug Expert Committee (CDEC)
  - pan-Canadian Oncology Drug Review Expert Review Committee (pERC)
  - Health Technology Expert Review Panel (HTERP)
  - Formulary Management Expert Committee (FMEC)
  - Patient and Community Advisory Committee (PCAC)

Clinician Engagement

Clinicians and clinician associations contribute to our work in various ways.

- They sit as members of our expert committees:
  - Canadian Drug Expert Committee (CDEC)
  - pan-Canadian Oncology Drug Review Expert Review Committee (pERC)
  - Health Technology Expert Review Panel (HTERP)
- They act as clinical experts during the review process
- As individuals or associations, they provide input into the review

Canada's Drug and
Health Technology Agency

2024 Call for Nominations

CADTH is seeking nominations for its expert and advisory committees.

Apply now at:

cadth.info/call-for-nominations

More Information and How to Get Involved

www.cadth.ca/pain

Want to Be Involved as a Patient or Clinician?

Subscribe to our Weekly Summary for information on:

- open calls for input
- drugs under review

Email: requests@cadth.ca




cadth